Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/page/4/?d=1Neue Studien: Psoriasis im JDDGdeKlinische und histopathologische Merkmale fortgeschrittener Plattenepithelkarzinome der Haut mit unterschiedlichem Ansprechen auf Cemiplimabhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/klinische-und-histopathologische-merkmale-fortgeschrittener-plattenepithelkarzinome-der-haut-mit-unterschiedlichem-ansprechen-auf-cemiplimab-r49/No abstract supplied.

Weiterlesen

]]>49Fri, 30 May 2025 15:05:38 +0000A novel nomogram to predict psoriatic arthritis in patients with plaque psoriasis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-novel-nomogram-to-predict-psoriatic-arthritis-in-patients-with-plaque-psoriasis-r48/ObjectiveTo construct a predictive model for Psoriatic Arthritis (PsA) based on clinical and ultrasonic characteristics in patients with plaque psoriasis (PsP).

Patients and methods

Demographic, clinical, and ultrasound data were collected from patients with PsP and PsA between May 2019 and December 2022.

Results

A total of 212 patients with PsP and 123 with PsA in the training cohort, whereas the validation cohort comprised 91 patients with PsP and 49 with PsA. The multivariate logistic regression identified nail psoriasis (odds ratio [OR] 1.88, 95% CI: 1.07-3.29), synovitis (OR 18.23, 95% CI: 4.04-82.33), enthesitis (OR 3.71, 95% CI: 1.05-13.14), and bone erosion (OR 11.39, 95% CI: 3.05-42.63) as effective predictors for PsA. The area under the curve was 0.750 (95% CI, 0.691-0.806) and 0.804 (95% CI, 0.723-0.886) for the training and validation cohorts, respectively. The Hosmer-Lemeshow goodness-of-fit test showed good consistency for both the training cohort (p  =  0.970) and the validation cohort (p  =  0.967). Calibration curves also indicated good calibration for both cohorts. The DCA revealed that the predictive model had good clinical utility.

Conclusions

We have developed a quantitative, intuitive, and convenient predictive model based on nail psoriasis, synovitis, enthesitis, and bone erosion to assess the risk of PsA in patients with plaque psoriasis.

Weiterlesen

]]>48Fri, 30 May 2025 15:05:38 +0000Clinicopathological characteristics of low-dose methotrexate-induced epidermal dysmaturation: A study of 22 patients.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/clinicopathological-characteristics-of-low-dose-methotrexate-induced-epidermal-dysmaturation-a-study-of-22-patients-r47/Background and objectiveErosions of the skin and mucous membranes with epidermal dysmaturation are a known side effect of cytostatic chemotherapy regimens and can also be observed during low-dose methotrexate (MTX) therapy. The study aimed to delineate the clinical and histopathological alterations.

Patients and methods

A database search of the archive for dermatopathology was conducted, identifying 22 patients who developed epidermal dysmaturation on low-dose MTX. Clinical and laboratory changes, along with an array of histologic parameters were analyzed and statistically evaluated using SPSS.

Results

Patients were predominantly female with a mean age of 69.1 years. The main indications were psoriasis vulgaris and rheumatoid arthritis. Clinically, patients mostly presented erosive plaques at the injection site, on mucosal surfaces, and disseminated lesions. Most patients showed normal laboratory values. Histopathologically, key findings included enlarged keratinocytes with pale cytoplasm and enlarged nuclei with prominent nucleoli, along with the degeneration of the basal layer. Consistent observations in the dermal compartment included infiltration of neutrophilic granulocytes, lymphocytes, and histiocytes.

Conclusions

This study proposes clinicopathological criteria for the diagnosis of MTX-associated skin toxicity, aiming to increase awareness among clinicians and pathologists for early diagnosis. Early recognition can prevent potentially life-threatening progression.

Weiterlesen

]]>47Fri, 30 May 2025 15:05:38 +0000Therapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinibhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/therapie-eines-schweren-gemischten-handekzems-und-generalisierten-ekzems-mit-dem-jak%E2%80%90inhibitor-upadacitinib-r41/No abstract supplied.

Weiterlesen

]]>41Thu, 29 May 2025 18:10:57 +0000Screening of psoriatic arthritis by dermatologists - a German nationwide survey.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/screening-of-psoriatic-arthritis-by-dermatologists-a-german-nationwide-survey-r40/Background and objectivesUp to 30% of psoriasis (PsO) is clinically associated with psoriatic arthritis (PsA). A large proportion of new onset of PsA is diagnosed at a later stage, despite the necessity of early effective treatment to prevent structural damage. This study aimed to identify the routine screening practices used for PsA in patients with PsO.

Patients and methods

This non-interventional, prospective, epidemiological, cross-sectional study conducted in Germany focuses on screening activity and treatment selection of dermatological practices in suspected PsA. Descriptive statistics and patient characteristics were analyzed for different center types.

Results

One hundred ninety-five patients from 34 office-based physicians, five non-university hospitals, and nine university hospitals were included. Questionnaires or imaging techniques were not routinely used (< 45%). Especially, ultrasounds (≤ 5%) and MRIs (< 6.3%) were rarely performed. Between 30% and 75% of suspected PsA could be confirmed. Referral to rheumatologists and/or appropriate therapy initiation were the most frequent consequences.

Conclusions

Results of this study reflect the status of PsA screening activity by dermatologists. Imaging techniques, particularly ultrasound or MRIs to detect early forms of PsA, were inadequately used, which may have contributed to continued underdiagnoses. Collaboration between dermatologists and rheumatologists should be reviewed with a view to improving effective PsA screening.

Weiterlesen

]]>40Thu, 29 May 2025 18:10:57 +0000Long-term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/long-term-remission-and-normal-pregnancy-with-successful-delivery-in-a-patient-with-generalized-pustular-psoriasis-after-spesolimab-r39/No abstract supplied.

Weiterlesen

]]>39Thu, 29 May 2025 18:10:57 +0000Grover's disease-like patterns in early pityriasis rubra pilaris.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/grovers-disease-like-patterns-in-early-pityriasis-rubra-pilaris-r38/No abstract supplied.

Weiterlesen

]]>38Thu, 29 May 2025 18:10:57 +0000Update Vulvadermatologie – Diagnostik und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/update-vulvadermatologie-diagnostik-und-therapie-r37/No abstract supplied.

Weiterlesen

]]>37Thu, 29 May 2025 18:10:57 +0000Impact of a dermatological rehabilitation program on cardiovascular risks of psoriasis patients.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/impact-of-a-dermatological-rehabilitation-program-on-cardiovascular-risks-of-psoriasis-patients-r36/Background and objectivesPsoriasis vulgaris is a common chronic inflammatory skin disease, associated with multiple cardiovascular comorbidities, which can ultimately lead to increased mortality. Dermatological rehabilitation programs represent an additional therapeutic option in patients with psoriasis besides the classical outpatient or inpatient management. This study aimed to investigate the impact of dermatological rehabilitation on cardiovascular risk factors, cardiorespiratory fitness and quality of life at the Clinic of Dermatology, Bad Bentheim, Germany.

Patients and methods

This prospective study included 105 patients (age > 18 years) with known psoriasis and/or psoriasis (pustulosa) palmoplantaris committing to a 3-week long rehabilitation program. Various patient reported outcomes including dermatological life and quality index, patient global assessment, physical activity, pruritus and smoking and alcohol consumption history were captured. Body mass index (BMI) and physical fitness were also assessed. Study parameters were collected by telephone at baseline, at discharge, and at 3 and 6 months.

Results

Significant improvements in cardiorespiratory fitness (p < 0.001), BMI (p < 0.001), quality of life (p < 0.001), patients subjective estimation of disease severity (p < 0.001) and psoriasis area and severity index (p < 0.001) were shown.

Conclusions

The findings emphasize the importance of a rehabilitation program for patients with psoriasis due to its positive and sustained effects on cardiovascular risk factors.

Weiterlesen

]]>36Thu, 29 May 2025 18:10:57 +0000Update vulval dermatology - diagnostics and therapy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/update-vulval-dermatology-diagnostics-and-therapy-r35/Weiterlesen

]]>35Thu, 29 May 2025 18:10:57 +0000Kutane Impfreaktionenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/kutane-impfreaktionen-r34/No abstract supplied.

Weiterlesen

]]>34Thu, 29 May 2025 18:10:57 +0000Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/hair-regrowth-in-a-patient-with-alopecia-universalis-and-psoriasis-vulgaris-during-deucravacitinib-therapy-r33/No abstract supplied.

Weiterlesen

]]>33Thu, 29 May 2025 18:10:57 +0000History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross-sectional study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/history-clinical-presentation-therapy-and-patient-reported-outcomes-of-mucosal-lichen-planus-a-cross-sectional-study-r32/Background and objectivesMucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging.

Patients and methods

In this cross-sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023.

Results

On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%.

Conclusions

This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.

Weiterlesen

]]>32Thu, 29 May 2025 18:10:57 +0000Morbus‐Grover‐artige Muster in der Frühphase der Pityriasis rubra pilarishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/morbus%E2%80%90grover%E2%80%90artige-muster-in-der-fr%C3%BChphase-der-pityriasis-rubra-pilaris-r21/No abstract supplied.

Weiterlesen

]]>21Thu, 29 May 2025 17:51:46 +0000Cutaneous reactions to vaccination.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/cutaneous-reactions-to-vaccination-r20/Weiterlesen

]]>20Thu, 29 May 2025 17:51:46 +0000Anamnese, klinische Merkmale, Therapie und patientenberichtete Ergebnisse bei Lichen ruber mucosae: Eine Querschnittsstudiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/anamnese-klinische-merkmale-therapie-und-patientenberichtete-ergebnisse-bei-lichen-ruber-mucosae-eine-querschnittsstudie-r19/No abstract supplied.

Weiterlesen

]]>19Thu, 29 May 2025 17:51:46 +0000Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/wiederbehaarung-bei-einem-patienten-mit-alopecia-universalis-und-psoriasis-vulgaris-unter-deucravacitinib%E2%80%90therapie-r18/No abstract supplied.

Weiterlesen

]]>18Thu, 29 May 2025 17:51:46 +0000Indikation zur Systemtherapie bei Psoriasis: Kommentierte Checkliste für die Praxishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/indikation-zur-systemtherapie-bei-psoriasis-kommentierte-checkliste-f%C3%BCr-die-praxis-r17/No abstract supplied.

Weiterlesen

]]>17Thu, 29 May 2025 17:51:46 +0000Tofacitinib treatment for acquired reactive perforating collagenosis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/tofacitinib-treatment-for-acquired-reactive-perforating-collagenosis-r16/No abstract supplied.

Weiterlesen

]]>16Thu, 29 May 2025 17:51:46 +0000Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/epidemiology-of-generalized-pustular-psoriasis-in-germany-analyzing-factors-influencing-prevalence-estimates-health-insurance-data-r15/Background and objectivesGeneralized pustular psoriasis (GPP) is a rare, chronic, potentially life-threatening skin disease. We aimed to establish criteria to accurately approximate GPP prevalence in Germany.

Methods

A retrospective analysis of the WIG2 health claims database (1/1/2016-31/12/2020) was conducted. Patients aged ≥ 12 years continuously enrolled in their statutory health insurance with one inpatient or confirmed outpatient diagnosis code for GPP (International Classification of Diseases, 10th Revision [ICD-10] L40.1) were included. Scenarios with increasingly strict criteria were used to identify the GPP population.

Results

From 2016-2020, 5,236 potential GPP cases were identified based on a recorded GPP diagnosis. The scenario of ≥ 1 GPP diagnosis yielded the highest prevalence (336-390 patients/million) followed by > 1 GPP diagnosis in ≥ 2 quarters (189-288 patients/million); scenarios resulting in the lowest prevalence were diagnosis in ≥ 2 quarters AND two independent diagnoses (17-28/million) and diagnosis in ≥ 2 quarters AND two independent diagnoses or diagnosis by a specialist AND potential flare (58-61 patients/million).

Conclusions

This study suggests that diagnosis in ≥ 2 quarters by a specialist or two independent physicians may be the most clinically robust and reliable criteria for estimating GPP prevalence; therefore, 50-100 patients/million may represent a reasonable prevalence estimate range for Germany.

Weiterlesen

]]>15Thu, 29 May 2025 17:51:46 +0000Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/successful-treatment-of-subacute-cutaneous-lupus-erythematosus-with-the-tyk-2-inhibitor-deucravacitinib-in-a-patient-with-concomitant-psoriasis-vulgaris-r14/No abstract supplied.

Weiterlesen

]]>14Thu, 29 May 2025 17:51:46 +0000IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/il-17-and-il-23-inhibitors-dose-spacing-in-adult-psoriatic-patients-a-real-world-pilot-study-r13/Background and objectivesDe-escalation strategies of biologics in psoriasis treatment are widespread in clinical practice. Dose spacing consists of de-escalating the time range between biological drug injections.

Patients and methods

Major objectives were: to describe trends in mean PASI, PASI 100, 90, and ≤ 1 from baseline to 12 months after dose spacing, provide drug survival analysis of dose-spaced regimens, and concurrently describe phenotypic characteristics related to the selection of patient candidates for therapeutic dose spacing. A pre-post analysis was made between mean PASI at dose spacing and baseline, and after 3, 6, 9, and 12 months following dose spacing.

Results

Of 1,144 patients treated with IL-23 or IL-17 inhibitors, 61 patients underwent dose spacing. They presented with lower mean baseline Body Mass Index (BMI) (p = 0.011) and PASI (Psoriasis Area Severity Index) (p = 0.044) and were more frequently bio-experienced (p = 0.033). 12 months after dose spacing 42.9%, 85.7%, and 92.9% of observed patients achieved PASI 100, 90, and ≤1. There were no significant differences in mean PASI between dose spacing and subsequent time points. The dose spacing survival was 70% at 1 year.

Conclusions

Therapeutic modulation, such as dose spacing, is an effective strategy for most psoriasis patients, resulting in a clear or almost clear skin response that is maintained over time.

Weiterlesen

]]>13Thu, 29 May 2025 17:51:46 +0000Epidemiologie der generalisierten pustulösen Psoriasis in Deutschland: Analyse von Einflussfaktoren auf Prävalenzschätzungen aus Leistungsdaten der Krankenkassenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/epidemiologie-der-generalisierten-pustul%C3%B6sen-psoriasis-in-deutschland-analyse-von-einflussfaktoren-auf-pr%C3%A4valenzsch%C3%A4tzungen-aus-leistungsdaten-der-krankenkassen-r12/No abstract supplied.

Weiterlesen

]]>12Thu, 29 May 2025 17:51:46 +0000